Inspira Technologies, a breakthrough medical technology company, today announced that it has received notification of 510(k) class II clearance from the US Food and Drug Administration (FDA) for its INSPIRA ART100, a Cardiopulmonary Bypass System.
Dagi Ben Noon, CEO of Inspira, said “This is a proud moment for all of us at Inspira Technologies. We would like to thank all our investors and partners who have been with us on this journey to get here.”
Professor Benad Goldwasser, the Chairman of the Board of Inspira, stated: “We believe that the FDA clearance marks a clear example of the Company’s technological and innovative advancements.”
